NYSE:PFEPharmaceuticals
How Breakwater Trial Data At Pfizer (PFE) Has Changed Its Oncology Investment Story
Pfizer recently reported positive progression-free survival data from Cohort 3 of its Phase 3 BREAKWATER trial, where BRAFTOVI plus cetuximab and FOLFIRI outperformed FOLFIRI with or without bevacizumab in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
This result strengthens the case for expanding BRAFTOVI-based options in first-line colorectal cancer and adds further weight to Pfizer’s oncology pipeline story.
Next, we’ll examine how this new evidence for BRAFTOVI’s...